ఇండెక్స్ చేయబడింది
  • అకడమిక్ జర్నల్స్ డేటాబేస్
  • జెనామిక్స్ జర్నల్‌సీక్
  • అకడమిక్ కీలు
  • JournalTOCలు
  • చైనా నేషనల్ నాలెడ్జ్ ఇన్‌ఫ్రాస్ట్రక్చర్ (CNKI)
  • స్కిమాగో
  • వ్యవసాయంలో గ్లోబల్ ఆన్‌లైన్ పరిశోధనకు యాక్సెస్ (AGORA)
  • ఎలక్ట్రానిక్ జర్నల్స్ లైబ్రరీ
  • RefSeek
  • రీసెర్చ్ జర్నల్ ఇండెక్సింగ్ డైరెక్టరీ (DRJI)
  • హమ్దార్డ్ విశ్వవిద్యాలయం
  • EBSCO AZ
  • OCLC- వరల్డ్ క్యాట్
  • SWB ఆన్‌లైన్ కేటలాగ్
  • వర్చువల్ లైబ్రరీ ఆఫ్ బయాలజీ (విఫాబియో)
  • పబ్లోన్స్
  • మియార్
  • యూనివర్సిటీ గ్రాంట్స్ కమిషన్
  • జెనీవా ఫౌండేషన్ ఫర్ మెడికల్ ఎడ్యుకేషన్ అండ్ రీసెర్చ్
  • యూరో పబ్
  • గూగుల్ స్కాలర్
ఈ పేజీని భాగస్వామ్యం చేయండి
జర్నల్ ఫ్లైయర్
Flyer image

నైరూప్య

Overcoming Pseudomonas aeruginosa Resistance Caused by Glycocalyx with Tobracef

Manu Chaudhary, Renu Bansal and Anurag Payasi

The present study was aimed to compare the binding ability of selected chemicals (adjuvants) in 23 glycocalyx positive Pseudomonas aeruginosa isolates. Fractional inhibitory concentration indexes (FICindex) and drug uptake study were conducted using selected adjuvants. Whole-cell alkaline phosphatase assay was used for assessment of outer membrane permeability. FICindex was calculated using a microdilution checkerboard method. Among the drugs tested, Tobracef was found to be the most effective against all the selected clinical isolates with minimum inhibitory concentrations (MICs) of about 8-16 μg/ml. Tobracef without adjuvants showed drug uptake of approximately 85.3%. When Tobracef was combined with either adjuvant CH1 or adjuvant CH2 the drug uptake was increased to 90.6% and 94.8% respectively but this increase was not statistically significant (P>0.05). The drug uptake of other comparator drugs including ceftazidime, tobramycin, amikacin, gentamycin, ceftazidime plus amikacin without adjuvants varied from 14 to 34%. Addition of adjuvant CH2 and adjuvant CH1with these drugs enhanced the drug uptake by 8 to 11% and 11 to 22%, respectively which was statistically significant (P<0.01 with adjuvant CH2 and P<0.001 with adjuvant CH1). Tobracef without adjuvants showed maximum outer membrane permeability with 8.5 ± 0.70 permeability index at 8 hrs. Addition of adjuvant CH2 or adjuvant CH1 into Tobracef produced 9.1 ± 0.71 and 9.5 ± 0.98 permeability index which was statistically non-significant (P>0.05). Other comparator drugs exhibited a very low (only 2.4 to 3.5) permeability index and incorporation of adjuvant CH2 and adjuvant CH1 enhanced significantly the permeability index (P<0.01 with adjuvant CH2 and P<0.001 with adjuvant CH1). Interestingly, all the drugs showed additive effects when tested with both the adjuvants. However the exact mechanism of high membrane permeability of Tobracef is not known which needs to be explored. Thus, Tobracef is effective in dealing resistance from P. aeruginosa by increasing permeability and susceptibility towards P. aeruginosa.

నిరాకరణ: ఈ సారాంశం ఆర్టిఫిషియల్ ఇంటెలిజెన్స్ టూల్